Search Ctrl+K
Change language Switch ThemeSign In
[](https://www.bestblogs.dev/en/explore/brief "Daily Brief")[](https://www.bestblogs.dev/en/explore/newsletter "Weekly Picks")[](https://www.bestblogs.dev/en/explore/topics "Topics")[](https://www.bestblogs.dev/en/worldcup "World Cup Special")
[](https://www.bestblogs.dev/en/settings "Settings")[](https://www.bestblogs.dev/en/docs "Help Center")
Narrow Mode
86
千万粉“蓝衣女神”12 次化疗，最后一次化疗前又住院：她得的这种瘤，其实是“温和款”
Through influencer "Yi Li Xiao Sha Zi's" Hodgkin lymphoma treatment journey, this article corrects public misconceptions about "Stage III" and "12 rounds of chemotherapy," while explaining nodular sclerosis classical Hodgkin lymphoma's favorable prognosis and early warning symptoms. 梅 梅斯医学Follow·
Today·1680 words (about 7 min)
AI Summary & Key Points
Summary
The article uses the real case of influencer "Blue Dress Goddess" Xu Yi Sha as an entry point to detail the medical background of classical Hodgkin lymphoma nodular sclerosis type Stage III. The author corrects three major misconceptions: First, lymphoma's Ann Arbor staging differs from common cancers—Stage III is not terminal; Second, 12 rounds of chemotherapy follow ABVD regimen's standard dosing logic, fever and dizziness caused by accumulated chemotherapy toxicity and bone marrow suppression are common reactions, not disease progression; Third, young people should not dismiss persistent symptoms—Hodgkin's early symptoms are atypical and require vigilance. Combining professional knowledge with case studies, the article helps readers correctly understand the treatment patterns and prognosis of this disease, emphasizing the importance of seeking medical attention early.
Main Points
* 1. Hodgkin lymphoma nodular sclerosis type Stage III is a relatively favorable "gentle" subtype in the lymphoma family.
Classical Hodgkin lymphoma has low overall malignancy, and nodular sclerosis is the most common subtype. It predominantly affects people aged 15-35, is sensitive to chemotherapy, and can achieve a 5-year survival rate of over 80% with standard Stage III treatment.
* 2. 12 rounds of chemotherapy correspond to 6 cycles, which is the standard dosing logic of ABVD regimen.
ABVD regimen has a 21-day cycle, with medication administered once on days 1 and 15. Twelve treatments represent the standard protocol. Fatigue and fever in later stages are mostly caused by accumulated chemotherapy toxicity leading to bone marrow suppression, rather than disease progression.
* 3. Young people should not dismiss persistent "minor issues"; Hodgkin's early symptoms are atypical and require vigilance.
Symptoms such as cough, rib pain, night sweats, and weight loss may indicate B symptoms. If they persist for more than 2 weeks, one should check complete blood count and lymph node ultrasound. Early detection can significantly improve prognosis.
Sign in to highlight text and take notes as you read. Sign in now
关注 2026-07-07 07:50 上海
以下文章来源于：梅斯肿瘤新前沿 梅斯肿瘤新前沿 肿瘤新前沿是梅斯医学子频道，致力于为肿瘤医生提供科研干货、前沿资讯、研究进展、最新指南等。
6月30日，千万粉丝网红“一栗小莎子”发了条视频，配文“最后一次治疗前，记一下普通的一天，然后又又住院了，好事多磨吧”。镜头里的她戴着帽子，切了会儿菜、下楼走了两步就喘，说“治疗越到后面越累”，视频最后刚吃完饭又开始头晕、发烧。
评论区一片“加油”，但作为写过不少肿瘤科普的人，盯着她“经典型霍奇金淋巴瘤结节硬化型三期、12次化疗”的诊断，想和她以及所有刷到这条新闻的年轻人说几句实在话——她的病，并没有大家想的那么“凶险”。
先理清楚她的半年抗病时间线
“一栗小莎子”本名徐依莎，95年浙江温州人，浙工商日语系公费留日，2018年靠一条日语“我喜欢你”的视频初出圈，2021年蓝裙子舞蹈视频爆火成“蓝衣女神”，粉丝千万，确诊的时候孩子还不到两岁。
最初的信号是咳嗽两个月+肋骨疼，她想着“自己年轻没事，扛扛就好”，以为是骨折或者岔气，硬拖到2026年1月才去查，最终病理锤下来：经典型霍奇金淋巴瘤结节硬化型三期。1月23日她官宣停工化疗，总共要做12次。
中间三疗开始掉发，老公陪她一起剃了光头；4月她发视频说“病灶消了很多，还得打完六个疗程”——刚好对应12次：霍奇金标准化疗方案ABVD每个疗程21天，第1、15天各给药一次，6个疗程就是12次。现在走到最后一次前，又因为头晕发烧住了院。
第一个要纠的误区：淋巴瘤“三期”≠终末期
很多人一看“淋巴瘤+三期”就觉得完了，但其实淋巴瘤的分期和其他癌（比如肺癌、胃癌的TNM分期）完全不一样，它用的是Ann Arbor分期：I期是单个淋巴结区域受累，II期是膈肌同侧两个以上区域，III期才是病变越过膈肌，累及上腹部/腹腔淋巴结甚至脾，IV期才是广泛播散到结外器官。
更何况她得的是「经典型霍奇金淋巴瘤结节硬化型」——这甚至是淋巴瘤家族里预后排前几的“温和款”：霍奇金整体比非霍奇金恶性度低，结节硬化型又是经典型里最常见的亚型，高发于15-35岁的年轻人，对化疗极其敏感，III期患者规范治疗后的5年生存率能到80%以上。她4月说“病灶消了很多”完全符合这个病的治疗反应，真的不用瞎焦虑。
第二个要说的：12次化疗不是“遭罪次数”，是标准方案
她说的“12次化疗”对应“6个疗程”，就是刚才说的ABVD方案的常规给药逻辑。越到后面越累、甚至发烧，不是她体质差，是化疗的累积毒性：ABVD里的长春碱、达卡巴嗪都会抑制造血，多次治疗后骨髓储备越来越差，就会出现乏力、粒细胞缺乏，这时候一点小感染就会发烧——她视频里的“头晕发烧”大概率是进入了骨髓抑制期，这是化疗常见的不良反应，不是病情进展，处理及时很快能缓过来。
这里刚好要接她最初“扛扛就好”的坑：很多化疗患者觉得“发烧扛扛就好”，但化疗后粒细胞缺乏伴发热是急症，感染扩散速度比普通人快得多，必须立刻去医院，不能硬扛。
第三个要提醒年轻人的：别把“小毛病”扛成大问题
她最初咳俩月+肋骨疼，以为是骨折/岔气硬扛了俩月才查，这个坑真的太多年轻人踩：总觉得“我还年轻，不会得大病”“小毛病扛扛就好”。但其实霍奇金淋巴瘤的早期症状本来就不典型：除了颈部/锁骨上无痛性淋巴结肿大（最典型，但很多人没注意到），纵隔淋巴结肿大压到气管就会咳，骨受累就会疼，还有不明原因的盗汗、体重下降、低热，这些都属于淋巴瘤的“B症状”，只要持续2周以上没缓解，别自己瞎猜，去查个血常规、做个浅表淋巴结超声，几十块钱就能筛掉大部分问题，真有问题也能早抓。
最后
她这次是最后一次化疗前的小波折，病灶已经消了很多，按霍奇金的治疗规律，结束后再做几次评估如果完全缓解，后面定期复查就行，长期生存的概率很高。
其实她的抗癌日记最有意义的地方，不是“网红抗癌”的标签，是给所有年轻人提了个醒：年轻不是免死金牌，“扛扛就好”这四个字，有时候真的会扛出大问题。淋巴瘤是少数能通过规范化疗实现高长期生存率的恶性肿瘤，但前提是别拖，别硬扛。
参考来源：中国蓝新闻
来源 | 梅斯肿瘤新前沿
编辑 | 目兮
Key Quotes
> Being young is not a guarantee of immunity; those four words 'just tough it out' can sometimes lead to serious problems.
> Lymphoma is one of the few malignant tumors that can achieve high long-term survival rates through standardized chemotherapy, but the prerequisite is not to delay and not to tough it out.
Tags
Medical Science Popularization
Health & Wellness
Hodgkin Lymphoma
Cancer Treatment
Health Warning
Related Articles
* Does Long-Term Coffee Consumption Really Gradually Ruin Your Sleep? Latest Human EEG Study: Caffeine Can Reshape Sleep Structure and Rhythm at the Neurophysiological Level, Reducing Sleep Recovery Quality * Nature Sub-journal | How Ebola Virus 'Lurks' in the Brain for 120 Days? Brain Organoids Unravel the Mystery of Long-term Infection and Recurrence * Is "Masculinity" Declining and Cancer Risk Rising?! A Study of 26,000 Men: Lower Testosterone Concentrations (< 8.6 nmol/L) are Significantly Associated with Higher Cancer Mortality Risk, but Prostate Cancer is an Exception... is associated with an increased risk of cancer mortality, but testosterone shows no link to prostate cancer risk; instead, imbalances in SHBG and LH are the key factors.") * Professor Wang Yilong: From the Forbidden Zone of Thrombolysis to the Lancet, the Chinese TAPIS Study Breaks the 24h Post-Thrombolysis "Forbidden Zone", Providing a Chinese Evidence-Based Answer for Early Antithrombotic Therapy in Acute Ischemic Stroke * E235｜Can CAR-T Cure Cancer? A Conversation with Dr. Liu Cheng on CAR-T and the Future of Cancer Treatment * Milestone in Artificial Life! Chinese Team's Nature Breakthrough: First-Ever Realization of "One Mother Cell, Two Distinct Daughters" in Synthetic Cells
Make your daily reading actually fit you.A daily brief built from the sources you follow. Get started free HomeDiscoverWorld CupSettings